The impact of all acquisitions and investments in other entities during the nine months ended September 30, 2021, individually and collectively, on revenues, net income and total assets was not material and accordingly, pro forma financial information reflecting all acquisitions has not been presented.

2021

SCI Instruments

On August 24, 2021,

the Company acquired SCI Instruments (“SCI”), a privately held company, for a purchase price of $28.0 million with the potential for additional consideration of up to $4.0 million based on revenue and gross margin achievements in the calendar years 2022 and 2023. SCI is a manufacturer of advanced metrology systems and analysis software and serves major companies in the semiconductor, optoelectronics, data storage, display, MEMS, and optical coating industries. SCI will be integrated into the BSI Nano

segment

. The acquisition is being accounted for under the acquisition method. The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (dollars in millions):


Consideration Transferred:
Cash paid	$	28.0
Fair value of contingent consideration		1.0
Working capital adjustment		(1.0	)

Total consideration transferred	$	28.0

Allocation of Consideration Transferred:
Inventories	$	1.0
Other current and non-current assets		1.0
Intangible assets:
Technology		7.1
Customer relationships		6.4
Trade name		0.4
Backlog		1.2
Goodwill		12.6
Liabilities assumed		(1.7	)

Total consideration allocated	$	28.0

The preliminary fair value allocation included contingent consideration in the amount of $1.0 million, which represented the estimated fair value of future payments to the former shareholders of SCI based on achieving revenue and gross margin targets for the calendar years 2022 and 2023. The Company expects to complete the fair value allocation during the measurement period. The amortization period for the intangible assets acquired is ten years for the trade name and technology, and nine years for the customer relationships. The backlog intangible asset is expected to be fully amortized by December 31, 2021.

In addition to the SCI acquisition, in 2021 the Company completed acquisitions that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions):


Name of Acquisition	Date Acquired		Segment		Total Consideration		Cash Consideration
Creative Instruments		July 1, 2021		BSI Life Science	$	1.0	$	1.0
SVXR, Inc.		September 9, 2021		BSI Nano		14.0		11.9

					$	15.0	$	12.9

In addition to the acquisitions noted above, in the nine months ended September 30, 2021, the Company made investments in businesses complementary to its own portfolio. The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions):


Name	Acquisition / Investment		Date Acquired		Segment		Consideration		Cash Consideration
Glycopath Inc.		Investment		February 18, 2021		BSI Life Science	$	2.0	$	2.0
IonPath Inc.		Investment		March 18, 2021		BSI Life Science		2.0		2.0
Olaris, Inc.		Investment		September 23, 2021		BSI Life Science		0.5		0.5

							$	4.5	$	4.5